Stevanato Group (STVN) has released an update.
Stevanato Group S.p.A., a leading provider of pharmaceutical solutions, has reported a marginal revenue increase of 2% in the second quarter of 2024, reaching €259.6 million, with high-value solutions making up 40% of the total revenue. The company has revised its fiscal year 2024 guidance, with expected revenue between €1,090 million to €1,110 million, and adjusted EBITDA anticipated to be €264 million to €272 million. Challenges in the Engineering Segment due to project delays and higher costs have impacted profitability, but the company remains positive about its growth prospects and strong product demand.
For further insights into STVN stock, check out TipRanks’ Stock Analysis page.
